Table 2. Baseline population characteristics according to KRAS amino acid substitution.

	KRAS G12C (n=91)	KRAS G12V (n=85)	Other KRAS mutations (n=20)	P-value
Gender
Male	59 (65%)	60 (71%)	13 (65%)	0.7
Female	32 (35%)	25 (29%)	7 (35%)
Mean agea	64.4±11.27	63±9.1	63.5±9.16	0.68
Charlson comorbidity index
0	6 (7%)	9 (11%)	4 (20%)	0.17
1	39 (43%)	27 (32%)	8 (40%)
2	30 (33%)	23 (27%)	4 (20%)
3	16 (17%)	26 (30%)	4 (20%)
pT
1	9 (10%)	27 (32%)	7 (32%)	<0.0001
2	63 (69%)	26 (31%)	11 (55%)
3	15 (17%)	27 (32%)	2 (10%)
4	4 (4%)	5 (5%)	0
pN
N+	65 (71%)	83 (98%)	15 (75%)	<0.0001
N0	26 (29%)	2 (2%)	15 (25%)
Angio-invasion
Yes	24 (26%)	84 (99%)	12 (60%)	<0.0001
No	67 (74%)	1 (1%)	18 (4%)
Smoking habit
Never smoked	9 (10%)	9 (11%)	4 (20%)	0.33
Former smoker	33 (36%)	37 (44%)	10 (50%)
Active smoker	49 (54%)	39 (45%)	6 (30%)
Neo-adjuvant treatment
Yes	26 (29%)	32 (38%)	4 (20%)	0.22
No	65 (71%)	53 (62%)	16 (80%)
Type of neo-adjuvant treatment
Chemotherapy	22 (85%)	28 (88%)	3 (75%)	0.49
Radio-chemotherapy	4 (15%)	4 (12%)	1 (25%)
Adjuvant treatment
Yes	66 (73%)	83 (98%)	15 (75%)	<0.0001
No	25 (27%)	2 (2%)	5 (25%)
Type of adjuvant treatment
Chemotherapy	55 (83%)	81 (98%)	14 (93%)	<0.0001
Radiotherapy	1 (2%)	0	0
Radio-chemotherapy	10 (15%)	2 (2%)	1 (7%)
Lymph node ratio
<1/3	59 (91%)	7 (8%)	10 (67%)	<0.0001
⩾1/3	6 (9%)	76 (92%)	5 (33%)
Skip-N2
Yes	2 (8%)	0	2 (50%)	0.06
No	24 (92%)	1 (100%)	2 (50%)
Microscopic N
Yes	8 (12%)	5 (6%)	2 (13%)	0.36
No	57 (88%)	78 (94%)	13 (87%)
Number of N2 stations
1	17 (65%)	0	3 (75%)	0.36
2	9 (35%)	1 (100%)	1 (25%)
Resection margins
R0	90 (99%)	84 (99%)	20 (100%)	0.89
R1	1 (1%)	1 (1%)	0

Abbreviation: KRAS=V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue.

^aData are given as mean +/− standard deviation. Bold values were used to indicate significant variables.